INFO: Telaprevir (VX-950)

[Guest guest]

AASLD Conference Current status of Subjects Receiving Pegays and Ribavirin Follow-On Therapy After 28 Days Treatment with the Hepatitis C Protease Inhibitor Telaprevir ...www.natap.org/2006/AASLD/AASLD.htm - 15k - Cached - Similar pages Novartis, Idenix Suspend Tests on Hepatitis C Drug NM283 Vertex's hepatitis C drug telaprevir blocks the protease enzyme the virus needs to reproduce. Novartis bought rights to the Idenix drug a year ago for $455 ...www.natap.org/2007/HCV/071607_03.htm - 9k - Cached - Similar pages EASL, 42nd Annual Meeting of the European Association For The ... Interim Results Presented at EASL from PROVE 1 Clinical Trial of Investigational Drug Telaprevir in Patients with Genotype 1 Hepatitis C - (04/17/07) ...www.natap.org/2007/EASL/EASL.htm - 16k - Cached - Similar pages New Data for Investigational Hepatitis C Drug Telaprevir (VX-950 ... In addition, clinical investigators will report that 24 of 26 patients who received telaprevir (VX-950) in two early-stage clinical trials had undetectable

....www.natap.org/2006/AASLD/AASLD_02.htm - 16k - Cached - Similar pages VX-950 HCV Protease Inhibitor Resistance Profile: combination ... Telaprevir, also known as VX-950, is an oral HCV protease

inhibitor, ... VX05-950-103: first study of telaprevir incombination with pegylated interferon ...www.natap.org/2006/AASLD/AASLD_17.htm - 16k - Cached - Similar pages Vertex Pharmaceuticals Announces New Data for Investigational HCV ... Telaprevir (VX-950) is an investigational oral inhibitor of HCV protease, ... Vertex retains commercial rights to telaprevir in North America. ...www.natap.org/2007/EASL/EASL_02.htm - 16k - Cached - Similar pages VX-950 (Telaprevir): interim study results

phase II Anemia associated with telaprevir was grade 1 or 2. The incidence of severe declines in hemoglobin was the same for the VX950 or Peg/RBV control group. ...www.natap.org/2007/EASL/EASL_17.htm - 21k - Cached - Similar pages Combination Therapy With Telaprevir and Pegylated Interferon ... The study analyzed viral sequences isolated from patients receiving telaprevir (VX-950) as a single agent or in combination with peg-IFN in a Phase 1b ...www.natap.org/2007/HCV/020107_01.htm - 9k - Cached - Similar pages VX-950 Phase 2b PROVE 1 Study Interim Safety & Antiviral Activity ... "Results of First Interim Safety and Antiviral Analysis of the PROVE 1 Clinical Trial of Investigational HCV Protease Inhibitor Telaprevir (VX-950)" ...www.natap.org/2006/HCV/122006_06.htm - 13k - Cached - Similar

pages Interim Results Presented at EASL from PROVE 1 Clinical Trial of ... The data from PROVE 1 demonstrated a high rate of rapid viral response (RVR) in the telaprevir groups and a low rate of on-treatment viral breakthrough, ...www.natap.org/2007/EASL/EASL_12.htm - 18k - Cached - Similar pages Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and ... In conclusion, telaprevir dosing produced a rapid and dramatic reduction in viral load in all patients when given alone and in combination with ...www.natap.org/2007/HCV/081607_04.htm - 41k - Cached - Similar pages Vertex Pharmaceuticals Announces Results of First Interim Safety ... In the telaprevir dosing arms, the incidence of treatment discontinuations due to adverse events was 9% and the incidence of serious adverse events was 3%. ...www.natap.org/2006/HCV/122006_04.htm - 14k - Cached - Similar pages 12 weeks VX-950 Therapy Telaprevir-resistant variants (7-20 fold increase in IC50) may be eradicated mainly by PEG-IFN/RBV within 10-24 weeks (depending on the

effectiveness) ...www.natap.org/2007/DDW/DDW_36.htm - 14k - Cached - Similar pages